{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:15:36Z","timestamp":1786119336334,"version":"build-2736575974"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,9,10]]},"DOI":"10.1097\/qad.0b013e32832cbcec","type":"journal-article","created":{"date-parts":[[2009,8,25]],"date-time":"2009-08-25T03:12:37Z","timestamp":1251169957000},"page":"1829-1840","source":"Crossref","is-referenced-by-count":51,"title":["Characterization of virologic failure patients on darunavir\/ritonavir in treatment-experienced patients"],"prefix":"10.1097","volume":"23","author":[{"given":"Sandra","family":"De Meyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkki","family":"Lathouwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Dierynck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Els","family":"De Paepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Van Baelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Vangeneugden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Spinosa-Guzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaston","family":"Picchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Pierre","family":"de B\u00e9thune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R3-5-20210130","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jama.296.7.827","article-title":"Treatment for adult HIV infection. 2006 recommendations of the International AIDS Society\u2013USA Panel","volume":"296","author":"Hammer","year":"2006","journal-title":"JAMA"},{"key":"R4-5-20210130","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(06)69155-1","article-title":"The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised noninferiority trial","volume":"368","author":"Eron","year":"2006","journal-title":"Lancet"},{"key":"R5-5-20210130","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1128\/AAC.01136-06","article-title":"Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients","volume":"51","author":"Marin-Niebla","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R6-5-20210130","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/00002030-200403260-00008","article-title":"Long-term safety and durable antiretroviral activity of lopinavir\/ritonavir in treatment-naive patients: 4 year follow-up study","volume":"18","author":"Hicks","year":"2004","journal-title":"AIDS"},{"key":"R7-5-20210130","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/01.aids.0000216371.76689.63","article-title":"96-week comparison of once-daily atazanavir\/ritonavir and twice-daily lopinavir\/ritonavir in patients with multiple virologic failures","volume":"20","author":"Johnson","year":"2006","journal-title":"AIDS"},{"key":"R8-5-20210130","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/QAI.0b013e318074eff5","article-title":"Long-term efficacy and safety of tipranavir boosted with ritonavir in HIV-1-infected patients failing multiple protease inhibitor regimens: 80-week data from a phase 2 study","volume":"45","author":"Markowitz","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R10-5-20210130","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1310\/RRX7-49ME-27V7-MWWV","article-title":"Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers","volume":"5","author":"MacGregor","year":"2004","journal-title":"HIV Clin Trials"},{"key":"R11-5-20210130","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1128\/AAC.00560-06","article-title":"Plasma amprenavir pharmacokinetics and tolerability following administration of 1400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers","volume":"51","author":"Ruane","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R12-5-20210130","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1365-2125.2005.02436.x","article-title":"Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients","volume":"60","author":"Kappelhoff","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"R13-5-20210130","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jac\/dkh029","article-title":"Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients","volume":"53","author":"Zeldin","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"R14-5-20210130","first-page":"119","article-title":"Update of the drug resistance mutations in HIV-1: 2007","volume":"15","author":"Johnson","year":"2007","journal-title":"Top HIV Med"},{"key":"R15-5-20210130","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa012354","article-title":"Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection","volume":"346","author":"Walmsley","year":"2002","journal-title":"N Engl J Med"},{"key":"R16-5-20210130","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1517\/13543784.12.3.401","article-title":"The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy","volume":"12","author":"Becker","year":"2003","journal-title":"Expert Opin Investig Drugs"},{"key":"R17-5-20210130","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1086\/588675","article-title":"Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy","volume":"198","author":"Lima","year":"2008","journal-title":"J Infect Dis"},{"key":"R18-5-20210130","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/jac\/dkm364","article-title":"Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients","volume":"60","author":"Youle","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"R19-5-20210130","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1128\/AAC.49.6.2314-2321.2005","article-title":"TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates","volume":"49","author":"De Meyer","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"R20-5-20210130","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/QAD.0b013e32830285fb","article-title":"Efficacy and safety of once-daily darunavir\/ritonavir versus lopinavir\/ritonavir in treatment-na\u00efve HIV-1-infected patients at week 48","volume":"22","author":"Ortiz","year":"2008","journal-title":"AIDS"},{"key":"R21-5-20210130","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(07)61049-6","article-title":"Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial","volume":"370","author":"Madruga","year":"2007","journal-title":"Lancet"},{"key":"R22-5-20210130","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(07)60497-8","article-title":"Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials","volume":"369","author":"Clotet","year":"2007","journal-title":"Lancet"},{"key":"R23-5-20210130","first-page":"4","article-title":"Lack of major resistance mutations in HIV-1 protease at failure of boosted protease inhibitor-based first-line antiretroviral treatment","volume":"2","author":"Zazzi","year":"2007","journal-title":"Rev Antiviral Ther"},{"key":"R24-5-20210130","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0140-6736(08)61081-8","article-title":"Once-daily atazanavir\/ritonavir versus twice-daily lopinavir\/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-na\u00efve HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study","volume":"372","author":"Molina","year":"2008","journal-title":"Lancet"},{"key":"R27-5-20210130","first-page":"125","article-title":"Update of the drug resistance mutations in HIV-1: Fall 2006","volume":"14","author":"Johnson","year":"2006","journal-title":"Top HIV Med"},{"key":"R33-5-20210130","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/QAI.0b013e318183ac9c","article-title":"Influence of baseline protease inhibitor resistance on the efficacy of darunavir\/ritonavir or lopinavir\/ritonavir in the TITAN trial","volume":"49","author":"De Meyer","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R35-5-20210130","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/jac\/dkn544","article-title":"Mutations associated with virological response to darunavir\/ritonavir in HIV-1-infected protease inhibitor-experienced patients","volume":"63","author":"Descamps","year":"2009","journal-title":"J Antimicrob Chemother"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002030-200909100-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:05:16Z","timestamp":1786039516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002030-200909100-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,10]]},"references-count":24,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e32832cbcec","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9,10]]}}}